Skye Bioscience to Present at TD Cowen Health Care Conference
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biopharmaceutical company specializing in obesity and metabolic health disorders treatments, has announced its participation in the TD Cowen 45th Annual Health Care Conference.
CEO Punit Dhillon will deliver a corporate overview and be available for one-on-one meetings during the event. The presentation is scheduled for Wednesday, March 5, 2025, from 11:10 AM to 11:40 AM ET in Boston, MA. Interested parties can access both live and archived versions of the webcast through Skye's website.
Skye Bioscience (Nasdaq: SKYE), un'azienda biofarmaceutica in fase clinica specializzata nel trattamento dell'obesità e dei disturbi della salute metabolica, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute TD Cowen.
Il CEO Punit Dhillon presenterà una panoramica aziendale e sarà disponibile per incontri individuali durante l'evento. La presentazione è programmata per mercoledì 5 marzo 2025, dalle 11:10 alle 11:40 ET a Boston, MA. Le parti interessate possono accedere sia alle versioni in diretta che a quelle archiviate del webcast attraverso il sito web di Skye.
Skye Bioscience (Nasdaq: SKYE), una empresa biofarmacéutica en etapa clínica especializada en tratamientos para la obesidad y trastornos de la salud metabólica, ha anunciado su participación en la 45ª Conferencia Anual de Salud TD Cowen.
El CEO Punit Dhillon ofrecerá una visión general de la empresa y estará disponible para reuniones individuales durante el evento. La presentación está programada para miércoles, 5 de marzo de 2025, de 11:10 AM a 11:40 AM ET en Boston, MA. Las partes interesadas pueden acceder a versiones en vivo y archivadas del webcast a través del sitio web de Skye.
Skye Bioscience (Nasdaq: SKYE)는 비만 및 대사 건강 장애 치료를 전문으로 하는 임상 단계의 생명공학 회사로, TD Cowen 제45회 연례 건강 관리 회의에 참여한다고 발표했습니다.
CEO Punit Dhillon은 기업 개요를 발표하고 행사 동안 일대일 미팅을 위해 대기할 것입니다. 발표는 2025년 3월 5일 수요일, 오전 11:10부터 11:40까지 ET에 보스턴, MA에서 예정되어 있습니다. 관심 있는 분들은 Skye의 웹사이트를 통해 실시간 및 기록된 웹캐스트에 접근할 수 있습니다.
Skye Bioscience (Nasdaq: SKYE), une entreprise biopharmaceutique en phase clinique spécialisée dans le traitement de l'obésité et des troubles de la santé métabolique, a annoncé sa participation à la 45e Conférence Annuelle de Santé TD Cowen.
Le PDG Punit Dhillon présentera un aperçu de l'entreprise et sera disponible pour des réunions individuelles pendant l'événement. La présentation est prévue pour mercredi 5 mars 2025, de 11h10 à 11h40 ET à Boston, MA. Les parties intéressées peuvent accéder aux versions en direct et archivées du webinaire via le site Web de Skye.
Skye Bioscience (Nasdaq: SKYE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung von Fettleibigkeit und Stoffwechselerkrankungen spezialisiert hat, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt.
CEO Punit Dhillon wird einen Unternehmensüberblick geben und während der Veranstaltung für Einzelgespräche zur Verfügung stehen. Die Präsentation ist für Mittwoch, den 5. März 2025, von 11:10 bis 11:40 Uhr ET in Boston, MA, geplant. Interessierte Parteien können sowohl auf Live- als auch auf archivierte Versionen des Webcasts über die Website von Skye zugreifen.
- None.
- None.
SAN DIEGO, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that Punit Dhillon, Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the TD Cowen 45th Annual Health Care Conference.
- Presentation Date: Wednesday, March 5, 2025
- Time: 11:10 AM – 11:40 AM ET
- Location: Boston, MA
A live and archived webcast will be accessible on Skye’s website.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
FAQ
When is Skye Bioscience presenting at the TD Cowen Health Care Conference in 2025?
How can investors watch Skye Bioscience's presentation at the TD Cowen conference?
What is the focus of Skye Bioscience's research and development?
Will Skye Bioscience (SKYE) offer individual investor meetings at the TD Cowen conference?
